Determination of Human Body Burden Baseline Data of Platinum through Autopsy Tissue Analysis

by F. Vandiver P. Duffield,* Anna Yoakum,† Joseph Bumgarner,* and John Moran*

Results of analysis for platinum in 97 autopsy sets are presented. Analysis was performed by a specially developed emission spectrochemical method. Almost half of the individuals studied were found to have detectable platinum in one or more tissue samples. Platinum was found to be deposited in 13 of 21 tissue types investigated. Surprisingly high values were observed in subcutaneous fat, previously not considered to be a target site for platinum deposition. These data will serve as a human tissue platinum burden baseline in EPA's Catalyst Research Program.

Introduction

This report presents baseline data on various human tissue burdens of platinum. The work was done as part of the Environmental Protection Agency's catalyst research program, which includes some 18 tasks on health effects of the noble metals platinum and palladium. The impetus for the program was Title II provisions of the Clean Air Act of 1970, as amended, which requires reduction of CO, HC, and NO, emissions from light-duty motor vehicles. The automobile industry's response was the introduction of noble metal catalysts to reduce the regulated emissions. In California all American-made 1975 model automobiles would be equipped with noble metal catalytic converters; in the other 49 states, some 70% would be so equipped. The number of catalyst-equipped vehicles was estimated to increase rapidly over the next ten years, replacing the pre-1975 noncatalyst vehicle population at a rate of about 10%/yr (1). Since the employment of the noble metal catalytic converter represented introduction of a new environmental contaminant, it was imperative that a rather broad table.

| Table 1. Areas of study of noble metal health effects in EPA catalyst research program. |
|---------------------------------------------------------------|
| Emission characterization (Exhaust)                          |
| Measurement methodology development                         |
| Exhaust                                                      |
| Ambient air, water, soil                                    |
| Animal and human tissue, feces, urine                       |
| Standard reference material development                      |
| Bioenvironmental impact                                      |
| Methylation chemistry                                       |
| Population exposure studies                                  |
| Toxicology                                                   |
| Carcinogenicity                                              |
| Mutagenicity                                                 |
| Cytogenicity                                                 |
| Inhalation toxicology                                        |
| Sensitization (allergic response)                           |
| Irritation                                                   |
| Immunology                                                   |
| Body burden tissue analysis                                  |
| Health effects assessment                                    |

* Environmental Research Center, Environmental Protection Agency, Research Triangle Park, North Carolina 27711.
† Stewart Laboratories, Inc., 5815 Middlebrook Pike, Knoxville, Tennessee 37921.
integrated information base be developed very quickly. A listing of areas of study undertaken by EPA is presented in Table 1.

Objective

Determination of human tissue burdens of platinum prior to widespread use of the catalytic converter emerged as a key task among the program's areas of study. Future evaluations of noble metal health effects would depend in part upon the ability of researchers to compare baseline (pre catalyst) burdens with later human burdens.

Approach

During the winter of 1974-75, autopsy specimens were gathered through the Environmental Protection Agency's Community Health Environmental Surveillance System (CHESS) (2). Up to 21 tissue samples were taken from each of 97 autopsied individuals, of whom 95 had resided in southern California (Los Angeles area).

Tissue sample types analyzed (total 21) were prostate or uterus, thyroid, kidney, brain, gonad, adrenals, pancreas, heart (left ventricle), lung, liver, aorta (descending), muscle (psoas), subcutaneous fat, vertebrae (lumbar), fifth rib, femur, scalp hair, axillary hair, pubic hair, clavicle, and spleen.

Samples were frozen and shipped as soon as possible to Stewart Laboratories for analysis. The method for analysis had been developed by Stewart Laboratories and utilized an emission spectrochemical method for the determination of trace quantities of platinum, lead, and manganese in biological tissue. The analytical technique employed in the study—an emission spectrochemical method utilizing total energy burns in an argon-oxygen atmosphere—has been described previously (3). Although the method does not possess sufficient sensitivity to afford a total evaluation of residual baseline platinum concentrations in autopsy tissues, a detection limit of 10 parts per billion (ppb) can be obtained for a 1-g wet tissue sample. The analytical technique represents a method whose applicability is not dependent on the effectiveness of the sample preparation procedure to prepare a solution which is totally applicable to the potential complexities of platinum compounds which may be present. Total platinum in the sample is analyzed regardless of its chemical state since the method is limited only by its inherent sensitivity. As in all autopsy sample studies, sample size varied greatly.

In addition to the tissue analyses, the following data were available through the CHESS study for 92 of the 97 autopsy sets studied: age, race, sex, occupation, and cause of death. Clinical summaries, where available, were studied; there were no indications that platinum tumor suppressant therapy might have been a source of platinum exposure. Similarly, occupational information available did not indicate opportunity for occupational exposure to platinum.

Results

Of a total of 1313 samples obtained from the 97 individuals and analyzed for platinum, 62 contained detectable platinum concentrations. Of the 97 autopsied individuals, 45 had detectable concentrations of platinum in one or more tissue samples. Thus, though platinum was detected in only 5% of the samples analyzed, 46% of the individuals had detectable platinum in at least one type of tissue (see Table 2). The range of platinum concentrations detected was 0.003 to 1.46 \( \mu g/g \) (wet tissue); the mean value of detected platinum was 0.16 \( \mu g/g \), and the median value of detected platinum was 0.067 \( \mu g/g \).

Table 2. Individuals with detectable platinum concentrations.

|                      | Number | %  |
|----------------------|--------|----|
| Individuals in study | 97     | 100|
| Individuals with Pt in one or more detected tissue | 45 | 46 |
| Individuals with Pt in one tissue | (27) | (28) |
| Individuals with Pt in two tissues | (18) | (18) |
| Individuals without detected Pt | 52 | 54 |

The individual's age, sex, occupation, or major disease process cited as cause of death did not appear to be significant to platinum tissue burden. Age and sex characteristics of those individuals in whom platinum was detected in the tissues are presented in Table 3.

Table 3. Age and sex characterization of individuals showing detectable platinum concentrations.

|                      | Average age, yr | Male No. | %  | Female No. | %  | Unknown No. | %  |
|----------------------|-----------------|----------|----|------------|----|-------------|----|
| Total individuals in study | 61.5            | 39       | 40 | 52         | 54 | 6           | 6  |
| Individuals with detected Pt | 60.5            | 17       | 38 | 26         | 58 | 2           | 4  |
| Individuals with Pt detected in two tissue samples | 57.3            | 7        | 38 | 11         | 62 | 0           | 0  |
The apparent "target" sites for platinum deposition in the individuals studied, i.e., tissues in which the highest concentrations of platinum were found were, in descending order: subcutaneous fat, kidney, pancreas, and liver (Table 4).

Tissue deposition of detected platinum concentrations were plotted according to age and sex. Distribution profile followed the age and sex profile of the group fairly closely, so that there appears to be no particular age or sex bias for platinum concentration (Fig. 1).

**Discussion**

Two rather surprising observations were noted as a result of the autopsy data. First, platinum was present in detectable levels in one or more tissues in almost half of the individuals studied. It was thought that platinum would be an entirely new environmental contaminant, exposure to which had previously been occupational (mining, refining) only (I). Second, subcutaneous fat as a "target" site for platinum deposition was unexpected. Previous work with animals identified kidney, liver, and spleen as chief deposition sites for platinum (4,5). Perhaps level of exposure is important. The presence of platinum in subcutaneous fat raises the question of transport, since most platinum compounds are lipid-insoluble. Conversion to lipid-soluble compounds through methylation of platinum compounds is one possible explanation of potential significance.

Recent work by Taylor (6) has shown that at least two platinum compounds, platinic sulfate and potassium hexachloroplatinate, can be methylated via the same methylecobalamin (Me-B₁₂) reaction as involved in methylation of mercury.

---

**Figure 1.** Distribution of Pt detected in tissue by age group (15-90) and sex. The points (•) denote detectible Pt concentration.
No. samples showing Pt (% of samples in which Pt detected)

| Tissue sample type | No. samples analyzed | No. samples showing Pt (above detection limit) | % of samples in which Pt detected |
|--------------------|----------------------|-----------------------------------------------|-----------------------------------|
| Subcutaneous fat * | 74                   | 10                                            | 13.51                             |
| Kidney             | 91                   | 11                                            | 12.09                             |
| Pancreas           | 84                   | 10                                            | 11.90                             |
| Liver              | 90                   | 10                                            | 11.11                             |
| Brain              | 9                    | 1                                             | 11.11                             |
| Gonad              | 53                   | 5                                             | 9.43                              |
| Adrenals           | 60                   | 3                                             | 5.00                              |
| Muscle (psoas)     | 97                   | 4                                             | 4.12                              |
| Aorta (descending) | 92                   | 3                                             | 3.26                              |
| Heart (left ventricle) | 82          | 2                                             | 2.44                              |
| Spleen             | 52                   | 1                                             | 2.00                              |
| Prostate or uterus | 63                   | 1                                             | 1.59                              |
| Thyroid            | 73                   | 1                                             | 1.37                              |
| Lung               | 95                   | 0                                             | 0                                 |
| Vertebrae (lumbar) | 94                   | 0                                             | 0                                 |
| Fifth rib          | 97                   | 0                                             | 0                                 |
| Femur              | 57                   | 0                                             | 0                                 |
| Clavicle           | 30                   | 0                                             | 0                                 |
| Scalp hair         | 9                    | 0                                             | 0                                 |
| Pubic hair         | 1                    | 0                                             | 0                                 |
| Total              | 1313                 | 62                                            | 5.0                               |

* To determine whether this surprisingly high number of elevated levels might be the result of larger samples supplied in one batch (single hospital source), the average subcutaneous fat sample weight (μg of wet tissue) was computed for each batch. The batch in which seven of the ten levels were found averaged 20.78 μg per fat sample; the average weights for the other four batches were: 20.97, 14.44, 19.80, and 32.81 μg, respectively. Size of sample available for analysis may therefore be discounted as a factor.

Whether or not this reaction takes place in the normal environment or in the human body has not been established. Since it has been established that methylation can occur under laboratory conditions, EPA is planning a research program to determine biological activity of the methylated platinum product of this methylecobalamin reaction.

REFERENCES

1. Brubaker, P. E., et al. Noble metals: a toxicological appraisal of potential new environmental contaminants. Environ. Health Perspect. 10: 39 (1975).
2. Colucci, A., et al. Collection of autopsy tissue sets, CHESS pollutant burden protocol. Pollutant Burden Indicator Team, Human Studies Laboratory, National Environmental Research Center, EPA, Research Triangle Park, N. C. February 1973.
3. Yoakum, A., Stewart, P., and Sterrett, J. Method development and subsequent survey analysis of biological tissues for platinum, lead, and manganese content. Environ. Health Perspect. 10: 85 (1975).
4. Holbrook, D. J. Assessment of fuel additives emission toxicity via selected assays of nucleic acid and protein synthesis. EPA Contract-600/1-76-010a, U.S. Environmental Protection Agency, Research Triangle Park, N. C., 1976.
5. Durbin, P. A. Metabolic characteristics within a chemical family. Health Phys. 2: 225 (1960).
6. Taylor, R. T., and Hanna, L. Methylcobalamin: methylation of platinum with lead. Biomedical and Environmental Research Division, Lawrence Livermore Laboratories, University of California, Livermore, California. UCRL-77399, October 1975. Submitted to Environmental Letters.